Is surgery indicated in patients with stage IIIa lung cancer and mediastinal nodal involvement?

Interactive Cardiovascular and Thoracic Surgery

Volumn 13, Issue 3, 2011, Pages 303-310

  Bakir, Mohammed ^a   Fraser, Stephanie ^b   Routledge, Tom ^b   Scarci, Marco ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Lung cancer; N2; Stage III

Indexed keywords

ADULT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EVALUATION; COHORT ANALYSIS; HUMAN; INTERMETHOD COMPARISON; LOBECTOMY; LUNG CANCER; LUNG RESECTION; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT RESPONSE;

BENCHMARKING; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY, ADJUVANT; EVIDENCE-BASED MEDICINE; HUMANS; LUNG NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MEDIASTINUM; NEOPLASM STAGING; PATIENT SELECTION; PULMONARY SURGICAL PROCEDURES; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052581476     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1510/icvts.2011.267872     Document Type: Review

References (15)

1. Dunning J, Prendergast B, Mackway-Jones K. Towards evidence-based medicine in cardiothoracic surgery: best BETS. Interact CardioVasc Thorac Surg 2003;2:405-409.
2. Van Meerbeeck JP, Kramer GW, van Schil PE, Legrand C, Smit EF, Schramel F, Tjan-Heijnen VC, Biesma B, Debruyne C, van Zandwijk N, Splinter TA, Giaccone G. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:442-450.
3. Johnstone DW, Byhardt RW, Ettinger D, Scott CB. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); Final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002;54:365-369.
4. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-386.
5. Shepherd FA, Johnston MR, Payne D, Burkes R, Deslauriers J, Cormier Y, de Bedoya LD, Ottaway J, James K, Zee B. Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: A National Cancer Institute of Canada Clinical Trials Group Study. Br J Cancer 1998;78:683-685.
6. Stephens RJ, Girling DJ, Hopwood P, Thatcher N. A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer. Lung Cancer 2005;49:395-400.
7. Rusch VW, Crowley J, Giroux DJ, Goldstraw P, Im JG, Tsuboi M, Tsuchiya R, Vansteenkiste J. International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating; Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:603-612.
8. Casali C, Stefani A, Natali P, Rossi G, Morandi U. Prognostic factors in surgically resected N2 non-small cell lung cancer: the importance of patterns of mediastinal lymph nodes metastases. Eur J Cardiothorac Surg 2005;28:33-38.
9. Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, Brouchet L, Quoix E, Westeel V, Le Chevalier T. Survival of patients with resected N2 non-small cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:2981-2989.
10. Ratto GB, Costa R, Maineri P, Alloisio A, Bruzzi P, Dozin B. Is there a subset of patients with preoperatively diagnosed N2 non-small cell lung cancer who might benefit from surgical resection? J Thorac Cardiovasc Surg 2009;138:849-858.
11. Lorent N, De Leyn P, Lievens Y, Verbeken E, Nackaerts K, Dooms C, Van Raemdonck D, Anrys B, Vansteenkiste J. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 2004;15:1645-1653.
12. Decaluwé H, De Leyn P, Vansteenkiste J, Dooms C, Van Raemdonck D, Nafteux P, Coosemans W, Lerut T. Surgical multimodality treatment for baseline resectable stage IIIa-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg 2009;36:433-439.
13. Stefani A, Alifano M, Bobbio A, Grigoroiu M, Jouni R, Magdeleinat P, Regnard JF. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients. J Thorac Cardiovasc Surg 2010;140:356-363.
14. National Institute for Health and Clinical Excellence (NICE). The Diagnosis and Treatment of Lung Cancer (Update): Full Guideline London:NICE; 2011.
15. Lim E, Baldwin D, Beckles M, Duffy J, Entwisle J, Faivre-Finn C, Kerr K, Macfie A, McGuigan J, Padley S, Popat S, Screaton N, Snee M, Waller D, Wharburton C, Win T. Guidelines on the radical management of patients with lung cancer: British Thoracic Society and the Society for Cardiothoracic surgery in Great Britain and Ireland. Thorax 2010;65 (Suppl III).